WeightWatchers rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'

Yahoo Finance10-11

WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The weight-loss company, previously championed by the likes of Oprah Winfrey, saw ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474108772?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/hEWZt4wI.K90.G.NVFjlBg--~B/aD0zODQwO3c9NTc2MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2024-10/618b27d0-8739-11ef-bfde-b76dcbd93ed4","is_english":true,"pubTime":"2024-10-11 04:39","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474108772","market":"us","top_or_hot":-1,"title":"WeightWatchers rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'","media":"Yahoo Finance","content":"<div>\n<p>WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence.\nThe weight-loss company, previously championed by the likes of Oprah Winfrey, saw ...</p>\n\n<a href=\"https://finance.yahoo.com/news/weightwatchers-rallies-170-but-new-compounded-glp-1-drug-is-not-a-sustainable-long-term-business-model-203901327.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WeightWatchers rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWeightWatchers rallies 170%! But new compounded GLP-1 drug is 'not a sustainable long-term business model.'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 04:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/weightwatchers-rallies-170-but-new-compounded-glp-1-drug-is-not-a-sustainable-long-term-business-model-203901327.html><strong>Yahoo Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence.\nThe weight-loss company, previously championed by the likes of Oprah Winfrey, saw ...</p>\n\n<a href=\"https://finance.yahoo.com/news/weightwatchers-rallies-170-but-new-compounded-glp-1-drug-is-not-a-sustainable-long-term-business-model-203901327.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4192","symbol_name":"特殊消费者服务","start_time":0,"source_url":"https://finance.yahoo.com/news/weightwatchers-rallies-170-but-new-compounded-glp-1-drug-is-not-a-sustainable-long-term-business-model-203901327.html","article_id":"2474108772","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/hEWZt4wI.K90.G.NVFjlBg--~B/aD0zODQwO3c9NTc2MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2024-10/618b27d0-8739-11ef-bfde-b76dcbd93ed4"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474108772","pubTimestamp":1728592741,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"WeightWatchers  is trying to save its ailing business by betting on a market that threatens its very existence.The weight-loss company, previously championed by the likes of Oprah Winfrey, saw its stock spike this week after announcing that it will make copycats of Novo Nordisk's  Ozempic and Wegovy weight-loss drugs. WW International  stock jumped nearly 40% Wednesday following the news, and the stock climbed an additional 23% Thursday to close at $1.96. WW is up 172% from last week.Though WeightWatchers’ core business is its dieting program, the company has attempted to get in on the booming weight-loss drug market dominated by pharmaceutical giants Eli Lilly  and Novo Nordisk . . WeightWatchers first attempted to secure a foothold in the weighty drug space early last year with its acquisition of Sequence, a telehealth platform specializing in weight-loss medication management. The acquisition has failed to improve the company’s revenue, which fell 14.5% in 2023 and is expected to de","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4192":"特殊消费者服务","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","HIMS":"Hims & Hers Health Inc.","LLY":"礼来","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","BK4585":"ETF&股票定投概念","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","LU0385154629.USD":"贝莱德营养科学基金A2","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4196":"保健护理服务","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0058720904.USD":"联博国际健康护理基金A","LU0106831901.USD":"贝莱德世界金融基金A2","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","NVO":"诺和诺德","BK4007":"制药","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0122379950.USD":"贝莱德世界健康科学A2","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4590":"PTP","GLP":"全球合伙","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0971096721.USD":"富达环球金融服务 A","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","WW":"慧俪轻体","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BCS":"巴克莱银行","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4516":"特朗普概念"},"translate_title":"慧俪轻体上涨170%！但新的复方GLP-1药物“不是一种可持续的长期商业模式”。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"NVO":1,"HIMS":1,"GLP":1,"WW":0.9,"BCS":0.9},"content_text":"WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence.\nThe weight-loss company, previously championed by the likes of Oprah Winfrey, saw its stock spike this week after announcing that it will make copycats of Novo Nordisk's (NVO) Ozempic and Wegovy weight-loss drugs. WW International (i.e. WeightWatchers) stock jumped nearly 40% Wednesday following the news, and the stock climbed an additional 23% Thursday to close at $1.96. WW is up 172% from last week.\nThough WeightWatchers’ core business is its dieting program, the company has attempted to get in on the booming weight-loss drug market dominated by pharmaceutical giants Eli Lilly (LLY) and Novo Nordisk (NVO). (The strategy was championed by its former CEO Sima Sistani, who recently departed the company.) \nWeightWatchers first attempted to secure a foothold in the weighty drug space early last year with its acquisition of Sequence, a telehealth platform specializing in weight-loss medication management. The acquisition has failed to improve the company’s revenue, which fell 14.5% in 2023 and is expected to decline another 13% this year. \n\nWeightWatchers’ announcement Tuesday that it will offer compounded GLP-1 drugs is another shot at capitalizing on the market late in the game.  \nFederal laws allow companies to sell compounded versions of drugs on the US Food and Drug Administration’s shortage list. Regulations allow the drugs to be made at FDA-registered facilities, but the compounded medications themselves are not FDA-approved. WeightWatchers will offer a compounded semaglutide, the active ingredient in Ozempic and Wegovy. \nHere's the rub: Once the Novo Nordisk drugs are removed from the FDA’s shortage list, WeightWatchers will no longer be able to produce compounded semaglutide drugs at scale. Tirzepatide, the active ingredient in Eli Lilly's Mounjaro and Zepbound, was removed from the list last week, posing a massive problem for companies making compounded versions of the drug. \n\n\n\n  (AP Photo/Richard Drew, File)\n \n\n  ASSOCIATED PRESS\n \n\n“Compounding is not a sustainable long-term business model,” Barclays (BARC.L) healthcare technology and distribution analyst Stephanie Davis told Yahoo Finance. Davis is one of four Wall Street analysts covering the stock tracked by Bloomberg. Half of those analysts have Equal Weight ratings on WW, and Davis is one of the other two analysts who recommend selling the stock.\nMeanwhile, WeightWatchers’ expansion in the weight-loss drug space contradicts its core business. “GLP-1s are going to cannibalize the diet industry,” Davis said. \nWeightWatchers did not immediately respond to questions from Yahoo Finance on Thursday.\nTo illustrate the weakness of WeightWatchers’ strategy, Davis pointed to the rapid boom and bust of Hims & Hers Health (HIMS) stock. Shares of the telehealth company surged after news that it would sell Ozempic and Mounjaro copycats. The stock climbed 70% from the time of the announcement in May to a closing high of around $24.79 in mid-June. Then, when the FDA removed tirzepatide from its shortage list — meaning Hims & Hers would no longer be able to sell Eli Lilly weight-loss drug copycats at scale — HIMS tanked.\nHIMS shares dropped another 10% on Oct. 2 when the FDA published a letter citing concerns over compounded drugs — which are not reviewed for safety, effectiveness, or quality before they’re marketed.\nMore trouble for WW? Novo Nordisk on Oct. 8 published a study that found impurities in compounded versions of its drug — raising questions about the safety and efficacy of compounded semaglutide medications in particular. \nMorgan Stanley's (MS) Nathan Feather, on the other hand, believes that it’s not too late for WeightWatchers to turn things around. He said WeightWatchers’ failures to successfully monetize its GLP-1 telehealth offering — something it gained through its purchase of Sequence — has been due to its clients’ lack of insurance coverage for the drugs and the company's shortcomings in the advertising space, rather than weakness in its core business.\n“Given the sudden [market] share reversal [for WW International] was primarily due to the inability to compete in ad markets rather than consumer dissatisfaction with the Clinic program, we believe the launch of compounding addresses the primary constraint to growth,” Feather said in a note to investors Tuesday.\nHe added: “The bar for execution is high with diet season rapidly approaching” in addition to “investor concerns on the liquidity profile.”\nFeather maintains his Equal Weight rating on the stock, contending that WeightWatchers’ GLP-1 offering is only a temporary solution. “As GLP-1s are removed from the shortage list, this could lead to large-scale churn events if WW is unable to continue servicing clients using compounded medication,” he said.\n\n\n\n   StockStory aims to help individual investors beat the market.\n  \n\nLaura Bratton is a reporter for Yahoo Finance.\nClick here for the latest stock market news and in-depth analysis, including events that move stocks\nRead the latest financial and business news from Yahoo Finance","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474108772"}